Stimulating the development of drug treatments to improve cognition in schizophrenia

Annual Review of Clinical Psychology

Volumn 3, Issue , 2007, Pages 159-180

  Green, Michael F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

FDA; MATRICS; Neurocognition; NIMH

Indexed keywords

CLINICAL RESEARCH; COGNITION; COGNITIVE DEFECT; DRUG RESEARCH; FOLLOW UP; HUMAN; REVIEW; SCHIZOPHRENIA; TREATMENT PLANNING;

COGNITION DISORDERS; CONSENSUS; DRUG APPROVAL; DRUG EVALUATION; HEALTH POLICY; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); NEUROPHARMACOLOGY; NOOTROPIC AGENTS; RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES;

EID: 34247475722     PISSN: 15485943     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.clinpsy.3.022806.091529     Document Type: Review

References (104)

1. Addington J, Addington D. 1999. Neurocognitive and social functioning in schizophrenia. Schizophr. Bull. 25:173-82
2. Altshuler LL, Ventura J, van Gorp WG, Green MF, Theberge DC, Mintz J. 2004. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol. Psychiatry 56:560-69
3. Asarnow RF, Nuechterlein KH, Subotnik KL, Fogelson D, Torquato R, et al. 2002. Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention deficit hyperactivity disorder: the UCLA Family Study. Arch. Gen. Psychiatry 59:1053-60
4. Bellack AS, Green MF, Cook JA, Fenton W, Harvey PD, et al. 2006. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr. Bull. In press
5. Bellack AS, Sayers M, Mueser K, Bennett M. 1994. Evaluation of social problem solving in schizophrenia. J. Abnorm. Psychol. 103:371-78
6. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, et al. 2000. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157:549-59
7. Blanchard JJ, Cohen AS. 2006. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr. Bull. 32:238-45
8. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. 2006. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 163:418-25
9. Braff D. 1993. Information processing and attention dysfunctions in schizophrenia. Schizophr. Bull. 19:233-59
10. Brekke JS, Kay DD, Kee KS, Green MF. 2005. Biosocial pathways to functional outcome in schizophrenia. Schizophr. Res. 80:213-25
11. Brekke JS, Long JD, Nesbitt N, Sobel E. 1997. The impact of service characteristics from community support programs for persons with schizophrenia: a growth curve analysis. J. Consult. Clin. Psychol. 65:464-75
12. Bryson G, Bell MD. 2003. Initial and final work performance in schizophrenia: cognitive and symptom predictors. J. Nerv. Mental Dis. 191:87-92
13. Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, et al. 2005. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31:5-19
14. Cannon TD, Eyler-Zorrilla L, Shtasel D, Gur RC, Marco EJ, et al. 1994. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch. Gen. Psychiatry 51:651-61
15. Cannon TD, Huttunen MO, Lonnqvist J, Tuulio-Henriksson A, Pirkola T, et al. 2000. The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am. J. Hum. Genet. 67:369-82
16. Carpenter WT, Gold JM. 2002. Another view of therapy for cognition in schizophrenia. Biol. Psychiatry 51:969-71
17. Cornblatt B, Lenzenweger MF, Dworkin R, Erlenmeyer-Kimling L. 1992. Childhood attentional dysfunction predicts social deficits in unaffected adults at risk for schizophrenia. Br. J. Psychiatry 161:59-64
18. Cornblatt B, Obuchowski M, Roberts S, Pollack S, Erlenmeyer-Kimling L. 1999. Cognitive and behavioral precursors of schizophrenia. Dev. Psychopathol. 11:487-508
19. Coyle JT, Tsai G. 2004. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 174:32-38
20. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. 1999. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am. J. Psychiatry 156:1328-35
21. Dickerson F, Boronow JJ, Ringel N, Parente F. 1999. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. Schizophr. Res. 37:13-20
22. Dickerson FB, Boronow JJ, Stallings CR, Origoni AE, Cole S, Yolken RH. 2004. Association between cognitive functioning and employment status of persons with bipolar disorder. Psychiatr. Serv. 55:54-58
23. Dunning D, Heath C, Suis JM. 2004. Flawed self-assessment: implications for health, education, and the workplace. Psychol. Sci. Public Interest 5:69-106
24. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. 2005. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin. Neuropharmacol. 28:179-84
25. Evans JD, Heaton RK, Paulsen JS, McAdams LA, Heaton SC, Jeste DV. 1999. Schizoaffective disorder: a form of schizophrenia or affective disorder? J. Clin. Psychiatty 60:874-82
26. Finkelstein JRJ, Cannon TD, Gur RE, Gur RC, Moberg P. 1997. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. J. Abnorm. Psychol. 106:203-12
27. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, et al. 2001. The RAND/UCLA Appropriateness Users Manual. Santa Monica, CA: RAND Inst.
28. Fleck DE, Sax KW, Strakowski SM. 2001. Reaction time measures of sustained attention differentiate bipolar disorder from schizophrenia. Schizophr. Res. 52:251-59
29. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, et al. 2005. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology 181:358-63
30. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, et al. 2002a. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psychiatry 51:349-57
31. Friedman JI, Harvey PD, McGurk SR, White L, Parrella M, et al. 2002b. Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity. Am. J. Psychiatry 159:1388-94
32. Goff DC, Leahy L, Berman I, Posever T, Herz L, et al. 2001. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J. Clin. Psychopharmacol. 21:484-87
33. Gold JM. 2004. Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res. 72:21-28
34. Gold JM, Goldberg RW, McNary SW, Dixon L, Lehman AF. 2002. Cognitive correlates of job tenure among patients with severe mental illness. Am. J. Psychiatry 159:1395-401
35. Gold JM, Green MF. 2004. Neurocognition in schizophrenia. In Comprehensive Textbook of Psychiatry, ed. BJ Sadock, VA Sadock, pp. 1436-48. Baltimore, MD: Lippincott, Williams & Wilkins
36. Goldberg TE, Gold JM, Greenberg R, Griffin S. 1993. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am. J. Psychiatry 150:1355-62
37. Goldberg TE, Ragland JD, Torrey EF, Gold JM, Bigelow LB, Weinberger DR. 1990. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch. Gen. Psychiatry 47:1066-72
38. Goldman-Rakic PS, Castner SA, Svensson TS, Siever LJ, Williams GV. 2004. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174:3-16
39. Green MF. 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153:321-30
40. Green MF, Kern RS, Braff DL, Mintz J. 2000. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr. Bull. 26:119-36
41. Green MF, Kern RS, Heaton RK. 2004a. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 72:41-51
42. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, et al. 2002. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry 51:972-78
43. Green MF, Nuechterlein KH, Breitmeyer B. 1997. Backward masking performance in unaffected siblings of schizophrenia patients: evidence for a vulnerability indicator. Arch. Gen. Psychiatry 54:465-72
44. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, et al. 2004b. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56:301-7
45. Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. 2005. Social cognition in schizophrenia: recommendations from the MATRICS New Approaches Conference. Schizophr. Bull. 31:882-87
46. Hampson RE, Rogers G, Lynch G, Deadwyler SA. 1998. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J. Neurosci. 18:2740-47
47. Harvey PD, Keefe RSE. 2001. Studies of the cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158:176-84
48. Heaton R, Paulsen JS, McAdams LA, Kuck J, Zisook S, et al. 1994. Neuropsychological deficits in schizophrenics: relationship to age, chronicity, and dementia. Arch. Gen. Psychiatry 51:469-76
49. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. 1994. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am. J. Psychiatry 151:1409-16
50. Heinrichs RW, Zakzanis KK. 1998. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426-45
51. Helgason L. 1990. Twenty years' follow-up of first psychiatric presentation for schizophrenia: What could have been prevented? Acta Psychiatr. Scand. 81:231-35
52. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. 2004. Correlates of cognitive deficits in first episode schizophrenia. Schizophr. Res. 68:1-9
53. Keefe RSE, Poe M, Walker TM, Kang JW, Harvey PD. 2006a. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Ant. J. Psychiatry 163:426-32
54. Keefe RSE, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. 2006b. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. 81:1-15
55. Kern RS, Green MF, Nuechterlein KH, Deng BH. 2004. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr. Res. 72:11-19
56. Kirkpatrick B. 2006. Editor's introduction: theme issue on negative symptoms? Schizophr. Bull. 32:212-13
57. Klapow JC, Evans J, Patterson TL, Heaton RK, Koch WL, Jeste DV. 1997. Direct assessment of functional status in older patients with schizophrenia. Am. J. Psychiatry 154:1022-24
58. Kraemer HC. 1991. To increase power without increasing sample size. Psychopharmacol. Bull. 27:217-24
59. Kremen WS, Seidman J, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV 1994. Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophr. Bull. 20:103-19
60. Kremen WS, Seidman LJ, Faraone SV, Toomey R, Tsuang MT. 2000. The paradox of normal neuropsychological function in schizophrenia. J. Abnorm. Psychol. 109:743-52
61. Kurtz MM, Moberg PJ, Gur RC, Gur RE. 2001. Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis. Neuropsychol. Rev. 11:197-210
62. Laes JR, Sponheim SR. 2006. Does cognition predict community function only in schizophrenia? A study of schizophrenia patients, bipolar affective disorder patients, and community control subjects. Schizophr. Res. 84:121-31
63. Laughren T, Levin R. 2006. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 32:220-22
64. Laughren TP. 2003. Comorbid mood disorders and medical illness: a Food and Drug Administration perspective. Biol. Psychiatry 54:195-99
65. Marder SR, Fenton WS. 2004. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr. Res. 72:5-10
66. Martin LF, Kern WR, Freedman R. 2004. α-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174:54-64
67. Martínez-Arán A, Vieta E, Colom F, Torrent C, Sánchez-Moreno J, et al. 2004. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord. 6:224-32
68. McGurk SR, Mueser KT, Pascaris A. 2005. Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. Schizophr. Bull. 31:898-909
69. McKibbin CL, Brekke JS, Sires D, Jeste DV, Patterson TL. 2004. Direct assessment of functional abilities: relevance to persons with schizophrenia. Schizophr. Res. 72:53-67
70. Miller LS, Swanson-Green T, Moses JA, Faustman WO. 1996. Comparison of cognitive performance in RDC-diagnosed schizoaffective and schizophrenic patients with the Luria-Nebraska neuropsychological battery. J. Psychiatr. Res. 30:277-82
71. Mohamed S, Paulsen JS, O'Leary DS, Arndt S, Andreasen NC. 1999. Generalized cognitive deficits in schizophrenia. Am. J. Psychiatry 156:749-54
72. Moritz DJ, Kasi SV, Berkman LF. 1995. Cognitive functioning and the incidence of limitations in activities of daily living in an elderly community sample. Am. J. Epidemiol. 141:41-49
73. Mortiz S, Ferahli S, Naber D. 2004. Memory and attention performance in psychiatric patients: lack of correspondence between clinician-rated and patient-rated functioning with neuropsychological test results. J. Int. Neuropsychol. Soc. 10:623-33
74. Murray CJL, Lopez AD, eds. 1996. The Global Burden of Disease. Boston, MA: Harvard School Public Health
75. Niendam TA, Bearden CE, Rosso IM, Sanchez LE, Hadley T, et al. 2003. A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am. J. Psychiatry 160:2060-62
76. Nieuwenstein MR, Aleman A, de Haan EHF. 2001. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. J. Psychiatr. Res. 35:119-25
77. Nuechterlein KH. 1983. Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. J. Abnorm. Psychol. 92:4-28
78. Nuechterlein KH, Asarnow RF, Subotnik KL, Fogelson DL, Ventura J, et al. 1998. Neurocognitive vulnerability factors for schizophrenia: convergence across genetic risk studies and longitudinal trait/state studies. In Origins and Development of Schizophrenia: Advances in Experimental Psychopathology, ed. MF Lenzenweger, RH Dworkin, pp. 299-327. Washington, DC: Am. Psychol. Assoc.
79. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. 2004. Iden tification of separable cognitive factors in schizophrenia. Schizophr. Res. 72:29-39
80. Nuechterlein KH, Dawson ME, Green MF. 1994. Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia. Acta Psychiatr. Scand. 90:71-79
81. Nuechterlein KH, Green MF. 2006. MATRICS Consensus Cognitive Battery. Los Angeles, CA: MATRICS Assessment
82. Palmer BW, Heaton RK, Paulsen JS, Kuck J, Braff D, et al. 1997. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 11:437-46
83. Penn DL, Corrigan PW, Bentall RP, Racenstein JM, Newman L. 1997. Social cognition in schizophrenia. Psychol. Bull. 121:114-32
84. Perry W, Braff DL. 1994. Information-processing deficits and thought disorder in schizophrenia. Am. J. Psychiatry 151:363-67
85. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, et al. 2000. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, and haloperidol. Arch. Gen. Psychiatry 57:249-58
86. Rao SM, Leo GJ, Ellington L, Nauertz T. 1991. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41:692-96
87. Reichenberg A, Weiser M, Rabinowitz J, Caspi A, Schmeidler J, et al. 2002. A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am. J. Psychiatry 159:2027-35
88. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. 2004. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161:473-79
89. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, et al. 1991. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch. Gen. Psychiatry 48:618-24
90. Sergi MJ, Rassovsky Y, Nuechterlein KH, Green MF. 2006. Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am. J. Psychiatry 163:448-54
91. Snitz BE, MacDonald AW, Carter CS. 2006. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr. Bull. 32:179-94
92. Spitzer M. 1997. A cognitive neuroscience view of schizophrenic thought disorder. Schizophr. Bull. 23:29-50
93. Staubli U, Rogers G, Lynch G. 1994. Facilitation of glutamate receptors enhances memory. Proc. Nat. Acad. Sci. USA 91:777-81
94. Stirling J, White C, Lewis S, Hopkins R, Tantam D, et al. 2003. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr. Res. 65:75-86
95. Tugal Ö, Yazici KM, Yagcioglu AEA, Gögüs A. 2004. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 7:117-23
96. Twamley EW, Jeste DV, Bellack AS. 2003. A review of cognitive training in schizophrenia. Schizophr. Bull. 29:359-82
97. van Gorp WG, Altshuler L, Theberge DC, Wilkins J, Dixon W. 1998. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence: a preliminary study. Arch. Gen. Psychiatry 55:41-46
98. van Gorp WG, Baerwald JP, Ferrando SJ, McElhiney MC, Rabkin JG. 1999. The relationship between employment and neuropsychological impairment in HIV infection. J. Int. Neuropsychol. Soc. 6:534-39
99. Vauth R, Rusch N, Wirtz M, Corrigan PW. 2004. Does social cognition influence the relation between neurocognitive deficits and vocational functioning in schizophrenia? Psychiatry Res. 128:155-65
100. Velligan DI, Bow-Thomas C, Mahurin R, Miller AL, Halgunseth LC. 2000. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J. Nerv. Mental Dis. 188:518-24
101. Wexler BE, Bell MD. 2005. Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr. Bull. 31:931-41
102. Wiersma D, Wanderung J, Dragomirecka E, Ganev K, Harrison G, et al. 2000. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol. Med. 30:1155-67
103. Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8:457-72
104. Zakzanis KK. 1998. Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer's type. J. Clin. Exp. Neuropsychol. 20:259-69